This website uses cookies so that we can offer you the best possible user experience. The cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team to understand which sections of the website you find most interesting and useful.
*Click on each objective to get more information.
Open Innovation
- Incorporating models that enable the worldwide, public-private, patient-oriented co-development of programs and technologies with industrial partners in the area of pharmacogenomics research.
Collaborative research
- Integrating scientific teams from the global field in the search for new drugs and therapeutic targets for unmet medical needs applied to any disease, including rare diseases.
- Accelerating the application of new mechanisms based on translation and change in the drug discovery process.
- Seeking complementarity by opening up to collaborations in the global environment.
Innovation
- The easiest way to solve a labyrinth is to start at the exit. This is what we are doing at Kærtor, executing the reciprocal transfer in public-private co-development projects to immediately absorb the scientific advances into a new process, to find the shortest route through the labyrinth of drug discovery by entering through the clinical door.
Training and Entrepreneurship
- Promoting the training of different professionals in research, management and entrepreneurship to add value to the drug discovery ecosystem.
- Encouraging the creation of companies that close the gap between basic research in drug discovery and its industrial application, and contribute to the economical development of society.
- Collaborating with other entities in promoting the results of the research developed in the Foundation.